Understanding the extent to which early antiretroviral therapy (ART) can limit the establishment and persistence of the HIV reservoir is an important step to designing interventions aimed at achieving HIV cure. We measured the markers of HIV persistence and HIV-specific immunity in early treated children.
This is a cross-sectional study that enrolled 15 children older than 2 years of age who initiated ART before 6 months of age and had sustained viral suppression. Total and integrated HIV DNA, and 2-LTR circles in CD4+ T cells, HIV antibody response by fourth generation HIV enzyme immunoassay, and CD4+ and CD8+ T-cell responses to gag/env peptides by intracellular cytokine staining of CD4+ and CD8+ T cells were measured.
The median current age was 6.3 years and age at ART initiation was 17 weeks. The median duration of viral suppression was 6 years, and all had HIV RNA less than 50 copies/ml. The median CD4+ T cells was 44%. The median total HIV DNA was 132 copies/106 CD4+ T cells (range 11–1804) and integrated HIV DNA was 17 copies/106 CD4+ T cells (range 0–516), and no one had detectable 2-LTR circles. Nine of the 15 children (60%) had undetectable or extremely low integrated HIV DNA (<20 copies/106 CD4+ T cells). All except one (93%) had undetectable HIV-specific CD4+/CD8+ cell responses and seven (47%) had nonreactive enzyme immunoassay.
Early ART resulted in very low levels of markers of HIV persistence and undetectable HIV-specific immune responses in the majority of HIV-infected children who started ART before 6 months of age.
aThe HIV Netherlands Australia Thailand Research Collaboration
bSEARCH, The Thai Red Cross AIDS Research Center
cFaculty of Medicine, Department of Medicine
dFaculty of Medicine, Department of Pediatrics, Chulalongkorn University
eQueen Sirikit National Institute of Child Health
fFaculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
gKirby Institute of Infection and Immunity in Society, The University of New South Wales, Sydney, Australia
hVaccine and Gene Therapy Institute of Florida, Port St Lucie, Florida, USA.
Correspondence to Jintanat Ananworanich, MD, PhD, HIV-NAT, The Thai Red Cross AIDS Research Center, 104 Rajdumri Road, Pathumwan, 10330 Bangkok, Thailand. Tel: +66 2 255 7335; fax: +66 2 252 5779; e-mail: email@example.com
Received 18 October, 2013
Revised 9 December, 2013
Accepted 9 December, 2013